8-K: Amarin Reports Q1 2024 Results: European Growth Offsets US Decline, Share Repurchase Program Approved

Amarin's Q1 2024 results show strong European growth and a new patent extending exclusivity to 2039, while US revenue declined due to generic competition.

Summary

• Amarin reported its financial results for the first quarter of 2024, showing a mixed performance across different regions.
• In Europe, the company experienced significant growth, with in-market sales increasing by approximately 65% compared to the fourth quarter of 2023, driven by strong performance in Spain and the UK.
• A new European patent for VAZKEPA was granted, extending intellectual property protection until 2039.
• However, in the US, revenue declined by 41% compared to the first quarter of 2023 due to generic competition, although the US business remained profitable.
• Total net revenue for the quarter was $56.5 million, a decrease of 34% compared to $86.0 million in the same period last year.
• The company reported a net loss of $10.0 million, or $0.02 loss per share, compared to a net loss of $16.5 million, or $0.04 loss per share, in the first quarter of 2023.
• A share repurchase program of up to $50 million was approved by shareholders and is expected to commence following UK High Court approval in the second quarter of 2024.
• Amarin's cash position remains stable at $308 million.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to the significant revenue decline in the US market and the overall net loss, although the strong European growth and share repurchase program provide some positive aspects.

Positives

• The new European patent for VAZKEPA provides long-term intellectual property protection until 2039.
• Strong in-market sales growth in Europe, particularly in Spain and the UK, indicates successful market penetration.
• The US business remains profitable despite revenue decline, supporting operations in Europe.
• The share repurchase program could potentially increase shareholder value.
• Amarin's cash position remains stable, providing financial stability.
• Cost of goods sold decreased from $38.0 million to $24.6 million year-over-year.
• Selling, general and administrative expenses decreased from $59.6 million to $39.9 million year-over-year.

Negatives

• US product revenue declined significantly by 41% due to generic competition.
• Total net revenue decreased by 34% year-over-year.
• The company reported a net loss of $10.0 million for the quarter.
• Gross margin decreased from 70% to 55% year-over-year, excluding a one-time charge in Q1 2023.

Risks

• Continued generic competition in the US market could further erode revenue.
• The share repurchase program is subject to UK High Court approval, which may not be obtained.
• The company's success is heavily reliant on the European market, and any setbacks there could impact overall performance.
• Pricing and reimbursement negotiations in European markets could face challenges.
• The company's future performance is subject to various risks and uncertainties, as detailed in their SEC filings.

Future Outlook

Amarin believes its current cash and investments are adequate to support continued operations, including the share repurchase program, and is focused on cash preservation and investing in value-added opportunities. The company is on track to deliver $40 million of annual savings based on the reduction in force announced in July 2023.

Management Comments

• Our team continued to make progress across aspects of our business in the first quarter of 2024.
• In Europe, we successfully secured patent protection extending our intellectual property until 2039, which enhances the value of the business.
• Our team in Europe delivered ~65% in-market sales growth in the first quarter 2024 versus fourth quarter 2023, led by double-digit percentage increases in patients on therapy in Spain and the U.K., and continued to advance pricing and reimbursement efforts.
• In the U.S., a genericized market, revenues declined 41% versus first quarter 2023, primarily driven by net selling price due to generic competition.
• Overall, we are encouraged by the progress we have made in the first quarter, we remain confident in the business and are focused on enhancing the value of Amarin for the future.

Industry Context

The results highlight the challenges faced by pharmaceutical companies when their products face generic competition, particularly in the US market. The strong growth in Europe demonstrates the importance of geographic diversification and successful market access strategies. The focus on cardiovascular disease management aligns with the growing global concern about heart health.

Comparison to Industry Standards

• Amarin's European growth is notable, especially when compared to companies that have struggled to gain traction in new markets.
• The 65% in-market sales growth in Europe is significantly higher than the average growth rate for pharmaceutical products in the region.
• The 41% decline in US revenue due to generic competition is a common challenge faced by pharmaceutical companies, similar to what companies like Teva and Mylan have experienced with their generic products.
• The company's focus on cost reduction and cash preservation is a standard practice in the pharmaceutical industry when facing revenue declines.
• The share repurchase program is a common strategy used by companies to return value to shareholders, similar to programs implemented by companies like Pfizer and AbbVie.

Stakeholder Impact

• Shareholders may benefit from the share repurchase program, but may be concerned about the revenue decline in the US.
• Employees may be impacted by the ongoing cost reduction efforts.
• Customers in Europe may benefit from increased access to VAZKEPA.
• Suppliers may be affected by changes in production and distribution volumes.
• Creditors may be concerned about the company's net loss, but reassured by the stable cash position.

Next Steps

• Amarin expects to commence the share repurchase program following UK High Court approval in the second quarter of 2024.
• The company will continue to focus on pricing and reimbursement efforts in European markets.
• Amarin will continue to advance commercial launch, market access and regulatory progress across key territories in the Rest of World.
• The company will continue to focus on cash preservation and prudently invest in value-added opportunities.

Key Dates

Keywords

VAZKEPA, VASCEPA, Amarin, Cardiovascular, Patent, Europe, United States, Share Repurchase, Financial Results, Generic Competition, Icosapent Ethyl, Revenue, Net Loss